 |
|
Colon and Rectal Cancer Trial Results
1. Colorectal Cancer Drugs Require Careful Patient Selection
(Posted: 06/18/2008) - Patients with advanced colorectal cancer who have mutant forms of the gene KRAS in their tumors should not receive chemotherapy plus cetuximab (Erbitux), because they are unlikely to benefit from the treatment, according to findings presented at the 2008 ASCO meeting in Chicago.
2. Celecoxib Reduces Risk of Precancerous Colorectal Polyps: Five-Year Results of APC Trial
(Posted: 04/23/2008) - The five-year results of the Adenoma Prevention with Celecoxib (APC) trial indicate that two years after daily use of celecoxib (Celebrex®) has ended, there continues to be a modest reduction in the recurrence of colorectal polyps, according to a presentation at the 2008 American Association for Cancer Research annual meeting.
3. Drug Combination Cuts Risk of Advanced Colon Polyps
(Posted: 04/21/2008) - Low doses of two chemopreventive agents are highly effective at preventing the recurrence of the lesions that are often precursors to colorectal cancer, according to results presented at the 2008 American Association for Cancer Research annual meeting.
4. Cetuximab Provides Slight Survival Advantage in Advanced Colorectal Cancer
(Posted: 11/27/2007) - Use of the targeted agent cetuximab (Erbitux®) provides a small, but statistically significant improvement in overall survival in patients with colorectal cancer for whom prior therapies are no longer effective, according to the Nov. 15, 2007, New England Journal of Medicine.
5. Irinotecan Not Effective in Adjuvant Therapy for Colon Cancer
(Posted: 08/28/2007) - Irinotecan should not be added to 5-fluorouracil (5-FU) and leucovorin in the post-surgical treatment of stage III colon cancer, according to the Aug. 10, 2007, Journal of Clinical Oncology.
1 2 3 4 Next >
|
|
|
